Indiana Biosciences Research Institute Announces Research Partnership with Eli Lilly and Company

Indianapolis (November 17, 2025) — The Indiana Biosciences Research Institute (IBRI) is pleased to announce a new research partnership with Eli Lilly and Company (Lilly) focused on advancing the understanding of neural mechanisms that regulate energy balance and body weight.

The three-year initiative will include a multidisciplinary team of investigators at the IBRI led by Jonathan Douros, PhD, in collaboration with Stephanie Mowery, PhD and Patrick Knerr, PhD.

The study will examine the molecular pharmacology of amylin receptors in specific neuronal populations. These receptors are key targets for emerging obesity treatments.

“This project addresses a critical gap in our understanding of how central amylin signaling pathways influence metabolic and other therapeutic outcomes,” said Dr. Douros. “Our goal is to define amylin receptor function within specific areas of the brain.”